In the evolving landscape of metastatic colorectal cancer, managing patients with RAS/BRAF wild-type tumors remains a ...

In an interview with Targeted Oncology, Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, discusses the clinical necessity of overcoming resistance to first-generation EGFR ...

The global oncology sector is rocketing toward $668 billion in 2034[1], partly fueled by a massive structural pivot toward ...

Investigators assessed whether anticoagulation and platelet aggregation inhibition could have antitumoral effects when used along side targeted therapies for patients with unresectable stage III-IV ...

Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...

FRIDAY, Jan. 23, 2026 (HealthDay News) — Brain tumors are abnormal growths of cells in or around the brain. They can be ...

At 31 October 2025, net liabilities of the Group amounted to £8.4 million (30 April 2025: £3.8 million) and it held cash of £8.6 million (30 April 2025: £16.9 million). R&D tax credits of £3.0 million ...

The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application for a registrational phase 3 clinical trial of iSCIB1+ for patients with advanced melanoma, a step that ...

Unlocks path towards registrational Phase 3 trial planned to start in 2026Data from Phase 2 SCOPE trial show iSCIB1+ has potential to redefine ...

Filippo Pietrantonio, MD, discusses findings from the phase 1/2 OrigAMI-1 study in RAS/BRAF wild-type mCRC. With durable responses, encouraging survival outcomes, and evidence that some patients may ...

Rocatinlimab, targeting the OX40 pathway, shows significant efficacy in moderate to severe atopic dermatitis, marking a new therapeutic class in disease management. Long-term melanoma data reveal ...